非奈利酮在主要为晚期慢性肾脏病合并2型糖尿病且使用或不使用钠-葡萄糖协同转运蛋白2抑制剂治疗患者中的应用
FIDELIO-DKD研究纳入5674例2型糖尿病合并慢性肾脏病患者,随机接受非奈利酮或安慰剂。基线时259例(4.6%)使用SGLT-2i。非奈利酮降低尿白蛋白/肌酐比值,且不论基线是否使用SGLT-2i,肾脏和心血管复合结局获益一致。
要点
- 非奈利酮降低UACR,基线使用SGLT-2i者比值0.69,未使用者0.75,交互P=0.31。
- 非奈利酮显著降低肾脏复合结局和关键次要心血管复合结局,与基线SGLT-2i使用无关。
- 基线使用SGLT-2i者非奈利酮组高钾血症事件8.1%,未使用者18.7%。
核心结论
- 在已接受SGLT-2i治疗的2型糖尿病合并慢性肾脏病患者中,非奈利酮仍可改善UACR,且肾脏和心血管结局获益与是否使用SGLT-2i似乎一致。
研究设计与样本
- FIDELIO-DKD研究的事后分析,纳入5674例2型糖尿病、UACR 30至5000 mg/g、eGFR 25至<75 ml/min/1.73 m2且接受优化RAS阻断的患者,随机接受非奈利酮或安慰剂。
主要发现
- 基线使用SGLT-2i者259例(4.6%)。非奈利酮降低UACR的比值:使用SGLT-2i者0.69(95%CI 0.66-0.71),未使用者0.75(95%CI 0.62-0.90),交互P=0.31。
- 非奈利酮较安慰剂显著降低肾脏复合结局和关键次要心血管复合结局,基线SGLT-2i使用交互P分别为0.21和0.46,试验期间任意时间使用SGLT-2i亦无clear差异。
- 安全性在基线是否使用SGLT-2i间均衡,使用SGLT-2i组非奈利酮高钾血症事件8.1%,未使用者18.7%。
关键数值与推荐
- UACR变化以最小二乘均值比值表示:使用SGLT-2i者0.69(95%CI 0.66-0.71),未使用者0.75(95%CI 0.62-0.90)。
- 肾脏复合结局交互P=0.21,关键次要心血管复合结局交互P=0.46。
- 高钾血症事件:使用SGLT-2i者8.1%,未使用者18.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 基线使用SGLT-2i的患者仅259例(4.6%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on the treatment effect of finerenone. METHODS: Patients (N = 5674) with T2D, urine albumin-to-creatinine ratio (UACR) of 30 to 5000 mg/g and estimated glomerular filtration rate (eGFR) of 25 to <75 ml/min per 1.73 m2 receiving optimized renin-angiotensin system (RAS) blockade were randomized to finerenone or placebo. Endpoints were change in UACR and a composite kidney outcome (time to kidney failure, sustained decrease in eGFR ≥40% from baseline, or renal death) and key secondary cardiovascular outcomes (time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (ClinicalTrials.gov, NCT02540993). RESULTS: Of 5674 patients, 259 (4.6%) received an SGLT-2i at baseline. Reduction in UACR with finerenone was found with or without use of SGLT-2i at baseline, with ratio of least-squares means of 0.69 (95% CI = 0.66-0.71) and 0.75 (95% CI -= 0.62-0.90), respectively (P interaction = 0.31). Finerenone also significantly reduced the kidney and key secondary cardiovascular outcomes versus placebo; there was no clear difference in the results by SGLT-2i use at baseline (P interaction = 0.21 and 0.46, respectively) or at any time during the trial. Safety was balanced with or without SGLT-2i use at baseline, with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without). CONCLUSION: UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i.
引用
- Rossing P, Filippatos G, Agarwal R, et al. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2021. PMID: 35005312. doi:10.1016/j.ekir.2021.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。